Open AccessErlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer in the Era of Personalized Medicine
Author(s) -
Bivas Biswas
Publication year - 2015
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2014.57.5621
Subject(s) - medicine , erlotinib , docetaxel , lung cancer , oncology , personalized medicine , second line , cancer , epidermal growth factor receptor , first line , bioinformatics , biology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom